Galderma Group AG (XSWX:GALD) Other Long-Term Liabilities: CHF337 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF175.75
! 3 Warning Signs
View Full Analysis

What is Galderma Group AG Other Long-Term Liabilities?

Galderma Group AG XSWX:GALD -2.71% 15 Other Long-Term Liabilities is CHF337 Mil as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Galderma Group AG's other long-term liabilities for the quarter that ended in Jun. 2026 was CHF337 Mil.

Galderma Group AG's quarterly other long-term liabilities declined from Jun. 2025 (CHF392 Mil) to Dec. 2025 (CHF316 Mil) but then increased from Dec. 2025 (CHF316 Mil) to Jun. 2026 (CHF337 Mil).

Galderma Group AG's annual other long-term liabilities increased from Dec. 2023 (CHF401 Mil) to Dec. 2024 (CHF408 Mil) but then declined from Dec. 2024 (CHF408 Mil) to Dec. 2025 (CHF316 Mil).

Galderma Group AG Other Long-Term Liabilities Related Terms

Galderma Group AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Other Long-Term Liabilities Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
0.00 0.00 401.27 408.35 315.57

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial 381.65 408.35 391.96 315.57 337.30
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF337 Mil mean?
Galderma Group AG (XSWX:GALD) has a Other Long-Term Liabilities of CHF337 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Other Long-Term Liabilities too high?
Galderma Group AG's current Other Long-Term Liabilities is CHF337 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Other Long-Term Liabilities compare to ZTS and UTHR?
Galderma Group AG's Other Long-Term Liabilities of CHF337 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Other Long-Term Liabilities is CHF337 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Other Long-Term Liabilities of CHF337 Mil. The current Other Long-Term Liabilities is CHF337 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Other Long-Term Liabilities is CHF337 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF175.75
Price